The community-popular "Wolverine" peptide blend — BPC-157 (conventionally treated as local) plus TB-500 (conventionally treated as systemic). Used in community injury-recovery and post-op protocols; no Phase 2/3 human data.
The "Wolverine stack" combines two community-popular healing peptides. BPC-157 is a synthetic 15-amino-acid fragment of body protection compound (BPC), a larger protein found in human gastric juice — it is conventionally treated as a local agent in community use (rationale: short plasma half-life observed in animal studies; no human PK study confirms locality). TB-500 is a synthetic heptapeptide (Ac-LKKTETQ, 7 aa) corresponding to residues 17–23 of full-length Thymosin Beta-4 (Tβ4, 43 aa) — Phase 2 trials sometimes cited as "TB-500" (RGN-259, RGN-352, RGN-137) actually used full Tβ4, a different molecule. TB-500 is conventionally treated as a systemic agent (no human PK confirmation either).
Used alone, each component has well-documented preclinical literature but no Phase 2 or 3 human efficacy data (BPC-157), or no peer-reviewed human trial data of the heptapeptide specifically (TB-500). The "stack" framing — that combining them covers each other's gaps — is mechanistic speculation extrapolated from each compound's individual preclinical literature, not a finding from any combination study. As of May 2026, no peer-reviewed clinical or preclinical study has tested the combination as co-administered therapy. It is one of the most common peptide combinations in community and forum-driven injury-recovery protocols, particularly for tendon/ligament/post-surgical recovery — but its prevalence reflects community convention, not clinical-trial evidence.
Neither component is FDA-approved for any indication. BPC-157 has been on the FDA 503A Category 2 bulks list since 29-Sep-2023; the FDA's Pharmacy Compounding Advisory Committee is scheduled to reconsider new BPC-157 acetate / free-base nominations on 23–24 July 2026. TB-500 was procedurally removed from Category 2 on 22-Apr-2026 (nominators withdrew — not a safety determination); removal does not authorize compounding. TB-500 is also on the 23–24 July 2026 PCAC agenda. Neither component is legally compoundable in the US as of May 2026. Available as research chemicals only. WADA: BPC-157 = S0 (Non-Approved Substances); TB-500 = S2.3 (Peptide Hormones, Growth Factors).
Stimulates angiogenesis via VEGFR2 activation (Hsieh 2017, PMID 27847966), activates the FAK-paxillin pathway for fibroblast migration (Chang 2011, PMID 21030672), and upregulates GH receptors in tendon fibroblasts (Chang 2014, PMID 25415472). Typically injected near the injury site by community-practice convention; the rationale is the short plasma half-life seen in animal studies.
Sequesters G-actin via the LKKTETQ actin-binding motif preserved in TB-500. Full-length Tβ4 has been shown in animal/in vitro work to promote migration of stem cells, endothelial cells, and fibroblasts (Goldstein 2012 review, PMID 22074294; Malinda 1999 keratinocyte migration, PMID 10469335); whether TB-500 the heptapeptide reproduces this systemic distribution has not been characterized in human PK studies.
The mechanistic cartoon — BPC-157 quieting local inflammation and attracting new blood vessels, TB-500 "shipping in" the cells those vessels serve — is internally consistent and is the basis for the synergy pitch in community marketing. It has not been demonstrated in any peer-reviewed combination study. Whether the two compounds produce additive, synergistic, antagonistic, or neutral effects when co-administered is empirically unknown. Reports of "better than either alone" come from community/clinic anecdote, not controlled comparison.
As of May 2026, no peer-reviewed clinical trial — Phase 1, 2, or 3 — has been published on the BPC-157 + TB-500 combination in any species, in any indication, at any dose. No peer-reviewed preclinical study has tested the combination as a co-administered therapy. The benefits below are mechanistic hypotheses inferred from each compound's individual preclinical literature, projected onto the combination by analogy. They are not observed outcomes from combination trials. Synthesis sources: Vasireddi 2025 (PMID 40756949) systematic review of BPC-157 in orthopaedic sports medicine; McGuire 2025 (PMID 40789979) narrative review.
| Benefit | Evidence |
|---|---|
| Tendon & ligament | Animal: BPC-157 accelerated transected/detached Achilles tendon healing in rats (Krivic 2006, PMID 16583442; Chang 2011, PMID 21030672). TB-500 "amplification" via systemic migration is extrapolated from full-Tβ4; no peer-reviewed tendon/ligament study has tested the combination. |
| Muscle recovery | Animal: BPC-157 improved recovery from direct muscle trauma in rodent models; full-length Tβ4 improved skeletal muscle function in dystrophin-deficient mdx mice (Spurney 2010, PMID 20126456). No human study and no combination study. |
| Post-surgical | Animal: BPC-157 accelerated ileoileal anastomosis healing in rats (Vuksic 2007, PMID 17713731). Full-length Tβ4 has anti-fibrotic activity attributed largely to the N-terminal Ac-SDKP motif — which is not present in TB-500. Anti-scar performance of the heptapeptide should not be assumed to match full Tβ4. No human or combination data. |
| Joint pain | Anecdotal community reports; closest published anchor is an open-label uncontrolled n=12 case series of BPC-157 alone, intra-articular, in knee pain (Lee 2021, PMID 34324435). Not a combination study, not blinded, not controlled. No combination data. |
| Gut | Animal: BPC-157 has gastric-lesion-protection data in restraint-stress, ethanol, indomethacin, and capsaicin rodent models (Sikiric 1996, PMID 8769287). The Pliva PL-14736 Phase 2 ulcerative colitis trial was completed but never published — itself a negative signal. TB-500's "systemic" role is not a defined mechanism. |
| Neuroprotection | Animal: BPC-157 effects in rodent TBI / spinal-cord-damage models (Vukojevic 2022, PMID 34380875). Full-Tβ4 neurite/TBI data exists. Individual components only — no combination study. |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeThese figures reflect community-practice and veterinary-extrapolated dosing conventions. No human-validated dose exists for BPC-157, TB-500, or the combination. The 250–500 mcg/day BPC-157 range is allometrically scaled from Sikiric-group rat studies (~10 µg/kg); the 2–5 mg twice-weekly TB-500 range traces to veterinary/equine protocols and rodent extrapolation. No published Phase 1 SC dose-finding study exists for either component, and no PK/PD study has characterized their co-administration. WADA: BPC-157 = S0; TB-500 = S2.3 — both prohibited at all times, no TUE possible.
Some suppliers sell a pre-mixed "Wolverine" blend vial (common: 5 mg BPC + 5 mg TB-500 in one 10 mg total vial). Pre-mixed users typically follow a single dosing schedule for both components — but the standalone BPC-157 (daily) and TB-500 (twice-weekly) community-practice schedules are not aligned. Most pre-mix users follow the TB-500 twice-weekly schedule, which dilutes the BPC-157 portion 5–10× relative to the standalone BPC-157 protocol. No published study has compared pre-mix dosing to separate-vial dosing. Single injection is simpler; flexibility is sacrificed.
If using separate vials (preferred for flexibility), reconstitute each peptide independently with its own BAC water volume.
All compounds share one vial. Edit any amount or change the BPC-157 dose — the other doses scale by ratio.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Side effects are the union of both peptides' individual profiles — generally mild based on community report (no controlled safety study has surveilled either component or the combination). The cancer-risk concern is asymmetric: BPC-157's concern is theoretical (pro-angiogenic mechanism, no demonstrated tumor-promotion); TB-500's is mechanism-direct — full-length Tβ4 is overexpressed in colorectal, melanoma, hepatocellular, and pancreatic carcinomas with overexpression correlating with EMT/metastatic progression in published tumor-biology literature, and the actin-binding region preserved in TB-500 is partly responsible for the ILK-mediated EMT signal. The combination inherits the stronger of the two cautions, not the weaker.
No Phase 1 SC trial of either component or the combination has characterized the AE profile. The closest published human-exposure datum is a 2025 IV pilot, n=2, BPC-157 alone (Lee & Burgess 2025, PMID 40131143).
Cancer history is a strong contraindication, not merely theoretical. The two components' cancer concerns are asymmetric: BPC-157 is pro-angiogenic with no demonstrated tumor-promotion in human or rodent studies (theoretical concern). TB-500's parent molecule (full-length Tβ4) is overexpressed in colorectal, melanoma, pancreatic, and hepatocellular carcinomas, with overexpression correlating with EMT (epithelial-mesenchymal transition) and metastatic progression — driven in part by ILK activation and E-cadherin suppression, mechanisms partly conferred by the actin-binding region preserved in TB-500 (Tang 2011 PMID 21621326; Nemolato 2012 PMID 22233609; Cha 2003 PMID 14625258). Whether the heptapeptide reproduces this in vivo is unknown; the preclinical signal is mechanistically direct enough that active or prior malignancy of any kind is a strong contraindication, not a precautionary one. No combination safety study has been conducted.
Looking for BPC-157 + TB-500 (Wolverine Stack)? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeThe Wolverine stack combines two community-popular healing peptides: BPC-157 (a synthetic 15-amino-acid fragment of body protection compound) and TB-500 (a synthetic heptapeptide corresponding to residues 17 to 23 of full-length thymosin beta-4). It is one of the most common peptide combinations in community and forum-driven injury-recovery protocols, particularly for tendon, ligament, and post-surgical recovery. The nickname reflects the marketing pitch, not a clinical-trial finding.
The mechanistic cartoon is that BPC-157 quiets local inflammation and attracts new blood vessels via VEGFR2-driven angiogenesis and FAK-paxillin fibroblast migration, while TB-500 sequesters G-actin via its LKKTETQ motif and is conventionally treated as systemic to ship in cells those vessels serve. The combination is the basis for the synergy pitch in community marketing, but it has not been demonstrated in any peer-reviewed combination study. Whether the two compounds are additive, synergistic, antagonistic, or neutral when co-administered is empirically unknown.
No. As of May 2026, no peer-reviewed clinical trial (Phase 1, 2, or 3) has been published on the BPC-157 + TB-500 combination in any species, in any indication, at any dose. No peer-reviewed preclinical study has tested the combination as a co-administered therapy. The benefits listed in vendor copy are mechanistic hypotheses inferred from each compound's individual preclinical literature, not observed outcomes from combination trials.
Community-practice loading-phase dosing is 250 to 500 mcg BPC-157 daily (often split AM/PM) plus 2 to 5 mg TB-500 twice a week SubQ for 4 to 6 weeks. Maintenance is 250 mcg BPC-157 daily (or 500 mcg 3 times per week) plus 2 to 5 mg TB-500 weekly for another 4 to 8 weeks. These figures reflect community-practice and veterinary-extrapolated conventions; no human-validated dose exists for BPC-157, TB-500, or the combination.
Neither component is FDA approved for any indication. BPC-157 has been on the FDA 503A Category 2 bulks list since September 2023, and TB-500 was procedurally removed from Category 2 in April 2026 because nominators withdrew (not a safety determination). Removal does not authorize compounding. Neither component is legally compoundable in the US as of May 2026 and both are available as research chemicals only. WADA prohibits BPC-157 under S0 and TB-500 under S2.3 at all times, with no TUE possible.
Community-reported side effects include injection site reactions, fatigue or lethargy early in use (especially from TB-500), lightheadedness post-injection, and mild headache. The cancer-risk concern is asymmetric: BPC-157's concern is theoretical (pro-angiogenic, no demonstrated tumor-promotion), while TB-500's is mechanism-direct because full-length thymosin beta-4 is overexpressed in colorectal, melanoma, hepatocellular, and pancreatic carcinomas with overexpression correlating with EMT and metastatic progression. Active or prior malignancy of any kind is a strong contraindication.
Some suppliers sell a pre-mixed vial (commonly 5 mg BPC + 5 mg TB-500 in one 10 mg total vial). The trade-off is that the standalone BPC-157 daily and TB-500 twice-weekly schedules are not aligned. Most pre-mix users follow the TB-500 twice-weekly schedule, which dilutes the BPC-157 portion 5 to 10 times relative to the standalone protocol. Single injection is simpler, but flexibility is sacrificed and no published study has compared pre-mix dosing to separate-vial dosing.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.